Tilray Brands (TLRY) Non-Current Debt (2020 - 2026)
Tilray Brands' (TLRY) quarterly Non-Current Debt came in at $120.4 million in Q2 2026, down 18.9% YoY from $148.5 million in Q2 2025, and down 10.78% on a QoQ basis from $135.0 million in Q1 2026.
Tilray Brands (TLRY) Non-Current Debt (2020 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 7 years of Non-Current Debt data on file, last reported at $120.4 million in Q2 2026.
- Quarterly Non-Current Debt fell 18.9% year-over-year to $120.4 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $120.4 million (down 18.9% YoY) and the FY2026 annual result came in at $120.4 million, down 18.9% from the prior year.
- Non-Current Debt retreated to $120.4 million in Q2 2026, from $135.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $169.1 million in Q4 2023 to a low of $89.4 million in Q1 2023.
- A 5-year average of $139.3 million and a median of $144.2 million in 2025 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt sank 30.69% — and 2024, when it surged 85.25%.
- Tracing TLRY's Non-Current Debt over 5 years: stood at $152.2 million in 2022, then climbed by 11.14% to $169.1 million in 2023, then retreated by 11.96% to $148.9 million in 2024, then dropped by 6.81% to $138.7 million in 2025, then decreased by 13.2% to $120.4 million in 2026.
- The last three Non-Current Debt figures came in at $120.4 million (Q2 2026), $135.0 million (Q1 2026), and $138.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Tilray Brands | 519.72 Mn | 285.09 Mn | 90.52 Mn | 120.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 120.43 Mn |
| Feb 28, 2026 | 134.98 Mn |
| Nov 30, 2025 | 138.74 Mn |
| Aug 31, 2025 | 144.18 Mn |
| May 31, 2025 | 148.49 Mn |
| Nov 30, 2024 | 148.87 Mn |
| Aug 31, 2024 | 155.27 Mn |
| May 31, 2024 | 158.35 Mn |
| Feb 29, 2024 | 165.65 Mn |
| Nov 30, 2023 | 169.10 Mn |
| Aug 31, 2023 | 152.39 Mn |
| May 31, 2023 | 136.89 Mn |
| Feb 28, 2023 | 89.42 Mn |
| Nov 30, 2022 | 152.15 Mn |
| Aug 31, 2022 | 114.29 Mn |
| May 31, 2022 | 117.88 Mn |
| Feb 28, 2022 | 121.21 Mn |
| Nov 30, 2021 | 151.82 Mn |
| Aug 31, 2021 | 164.91 Mn |
| May 31, 2021 | 167.49 Mn |